China-based Qilu Pharmaceutical has announced the market launch of its generic version of AstraZeneca’s (AZ, NASDAQ: AZN) first-generation epidermal growth factor receptor (EGFR) inhibitor, Iressa (gefitinib), in the United States. This marks the debut of the first generic version of Iressa in the country, expanding access to this crucial medication for patients.
Historical Context and Market Entry
AstraZeneca initially secured approval for Iressa in the US in 2003, with a subsequent market entry in China one year later. Building on this legacy, Qilu Pharmaceutical launched its generic version of gefitinib in China in December 2016. Since then, other generic versions have been introduced by Chia Tai Tianqing, Kelun Pharma, and Hengrui Medicine, further increasing competition and accessibility in the Chinese market.
The Significance of Generic Iressa
The launch of Qilu Pharmaceutical’s generic Iressa in the US is a significant milestone, as it provides an alternative to the original EGFR inhibitor at a potentially more affordable price point. This development is expected to benefit patients who rely on EGFR inhibitors for the treatment of various conditions, including certain types of non-small cell lung cancer.-Fineline Info & Tech
